News

February 17, 2020February 17, 2020

Opdivo Extends Survival in Pretreated Advanced Stomach Cancer Patients, Phase 3 Trial Results Show

News

The immune checkpoint inhibitor Opdivo (nivolumab) may be a safe and effective treatment for people with advanced gastric or esophagogastric junction cancer who failed standard chemotherapy regimens, results from a Phase ... Read more

February 14, 2020February 14, 2020

Ilixadencel Improves Responses, Extends Survival in Newly-diagnosed Metastatic Kidney Cancer, Trial Results Show

News

Adding Immunicum‘s ilixadencel to standard surgical and medical treatment for newly-diagnosed metastatic renal cell carcinoma — the most common form of kidney cancer — increases patient responses, duration of response, and ... Read more

February 12, 2020February 12, 2020

Pepinemab-Bavencio Combo Shows Positive Anti-Tumor Activity in Advanced Lung Cancer, Phase 1/2 Trial Shows

News

A combination of Vaccinex‘s investigational antibody pepinemab and the immune checkpoint inhibitor Bavencio (avelumab) was well-tolerated and showed signs of lasting anti-tumor activity in patients with advanced non-small cell lung ... Read more

February 10, 2020February 10, 2020

Geneos to Test GNOS-PV02 Cancer Vaccine in Triple Combo Trial for Advanced Liver Cancer

News

Geneos Therapeutics is gearing up to initiate a Phase 1/2 trial of a triple immunotherapy combination, including its patient-specific cancer vaccine GNOS-PV02, in people with advanced hepatocellular carcinoma (HCC), ... Read more

February 7, 2020February 7, 2020

Bristol-Myers Squibb Withdraws European Application of Opdivo-Yervoy as Initial Treatment for Advanced NSCLC

News

Bristol-Myers Squibb has withdrawn its application to the European Medicine Agency (EMA) requesting the use of Opdivo (nivolumab) plus Yervoy (ipilimumab) combination therapy as a first-line treatment for people ... Read more

February 3, 2020February 14, 2020

First Patient Dosed in Proof-of-concept Study of CS1001 Plus Stivarga for Advanced Solid Tumors

News

CStone Pharmaceuticals has dosed the first patient in a clinical trial designed to evaluate CS1001, the company’s experimental PD-L1 inhibitor, in combination with Bayer’s Stivarga (regorafenib), for the treatment of ... Read more

January 27, 2020January 27, 2020

Newly Discovered T-cell Receptor May Lead to More ‘Universal’ Cancer Therapy, Study Suggests

News

A newly discovered receptor in T-cells — immune cells with the ability to kill tumors — makes these cells able to recognize and eliminate several cancer types, without harming ... Read more

January 27, 2020January 31, 2020

Cabometyx, Opdivo, Yervoy Triple Combo Shows Potential Benefits in Advanced HCC, Trial Data Show

News

A combination of Opdivo (nivolumab) and Cabometyx (cabozantinib), with or without Yervoy (ipilimumab), induces clinically meaningful responses in people with advanced hepatocellular carcinoma (HCC) — the most common type ... Read more

January 27, 2020February 6, 2020

NeoImmuneTech Cleared to Test Hyleukin-7, Keytruda Combo in Trial for Advanced Solid Tumors

News

NeoImmuneTech has been cleared to initiate a Phase 1b/2a trial to determine the optimal dosing and evaluate the anti-tumor activity of its Hyleukin-7 (NT-I7), used in combination with Merck’s ... Read more

January 23, 2020January 29, 2020

FDA to Review Tecentriq-Avastin Combo for Newly Diagnosed Advanced Liver Cancers

News

Genentech has submitted an application to the U.S. Food and Drug Administration to extend the use of Tecentriq (atezolizumab), in combination with Avastin (bevacizumab), for the treatment of people ... Read more

Pin It on Pinterest